Page 72 - ITPS-7-4

INNOSC Theranostics and
Pharmacological Sciences Role of saroglitazar in MASH

14. Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc diabetic dyslipidemia and non-alcoholic fatty liver disease:
treatment for adults with nonalcoholic steatohepatitis and Integrated analysis of the real-world evidence. Cardiovasc
fibrosis: Final analysis of the phase 2b CENTAUR study. Diabetol. 2019;18:80.
Hepatology. 2020;72(3):892-905. doi: 10.1186/s12933-019-0884-3
doi: 10.1002/hep.31108 22. Kumar DP, Caffrey R, Marioneaux J, et al. The PPAR
15. Sanyal AJ. Saroglitazar for nonalcoholic steatohepatitis: α/γ agonist saroglitazar improves insulin resistance
A randomized controlled double-blind trial. Hepatology. and steatohepatitis in a diet induced animal model of
2020;72(2), 719-731. nonalcoholic fatty liver disease. Sci Rep. 2020;10:9330.
16. Ratziu V. Saroglitazar, a PPAR-α/γ agonist, for treatment doi: 10.1038/s41598-020-66458-z
of non-alcoholic fatty liver disease: A randomized double- 23. Sarin SK. A prospective, multi-centre, double-blind,
blind placebo-controlled phase 2 trial. Lancet Gastroenterol randomized trial of Saroglitazar 4 mg compared to placebo
Hepatol. 2018;3(12):855-865. in patients with nonalcoholic steatohepatitis. Hepatol Int.
17. Aithal GP. Saroglitazar for the treatment of nonalcoholic 2020;14:S326.
steatohepatitis: A randomized controlled trial. J Hepatol. doi: 10.1007/s12072-020-10016-2
2016;65(2):289-295.
24. Gawrieh S, Noureddin M, Loo N, et al. A phase 2,
18. Sharma M. Long-term effects of saroglitazar on NASH and prospective, multicentre, double-blind, randomized study of
fibrosis in non-diabetic patients: A multicenter observational Saroglitazar magnesium 1 mg, 2 mg or 4 mg versus placebo
study. J Clin Gastroenterol. 2019;53(3):243-249. in patients with nonalcoholic fatty liver disease and/or
19. Kumar S. Saroglitazar in nonalcoholic fatty liver disease: nonalcoholic steatohepatitis (EVIDENCES IV). Hepatology.
A real-world observational study. Diabetes Obes Metab. 2019;70:1484A.
2017;19(5):721-724. 25. Zhang X, Wong GL, Wong VW. Application of transient
20. Goyal O, Nohria S, Goyal P, et al. Saroglitazar in patients with elastography in nonalcoholic fatty liver disease. Clin Mol
non-alcoholic fatty liver disease and diabetic dyslipidemia: Hepatol. 2020;26:128-141.
A prospective, observational, realworld study. Nat Res. doi: 10.3350/cmh.2019.0001n
2020;10:21117.
26. Jain MR, Giri SR, Bhoi B, et al. Dual PPARα/γ agonist
doi: 10.1038/s41598-020-78342-x saroglitazar improves liver histopathology and biochemistry
in experimental NASH models. Liver Int. 2018;38:1084-1094.
21. Kaul U, Parmar D, Manjunath K, et al. New dual peroxisome
proliferator activated receptor agonist-Saroglitazar in doi: 10.1111/liv.13634

Volume 7 Issue 4 (2024) 8 doi: 10.36922/itps.3560